Mahoney David L's Form 4 filing
Corcept Therapeutics Inc (CORT) · filed May 20, 2025
- Accession no.
- 0000950170-25-075470
- Filed
- May 20, 2025
- Trade date
- May 16, 2025
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 4 non-derivative transactions and 1 derivative transaction. Open-market sales total $2.03M. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Mahoney David LCIK 0001224091 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 16, 2025 | Common Stock | MOption exerciseAcquired | +30,000 | $6.55 | +$196,500 | 30,000 | Direct | |
| May 16, 2025 | Common Stock | FTax withholdingDisposed | −2,648 | $74.21 | −$196,508.08 | 27,352 | Direct | |
| May 16, 2025 | Common Stock | SSaleDisposed | −23,829 | $74.17F2 | −$1,767,396.93 | 3,523 | Direct | |
| May 16, 2025 | Common Stock | SSaleDisposed | −3,523 | $74.65F3 | −$262,991.95 | 0 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 16, 2025 | Common Stock | MOption exerciseDisposed | −30,000 | $0.00 | $0 | 0 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $73.54 to $74.525 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Referenced by the price of 1 transaction in Table I.
- F3
Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $74.54 to $74.80 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Referenced by the price of 1 transaction in Table I.
Remarks
The power of attorney under which this form was signed is on file with the Commission.